-
May 15, 2024 Apotex Corp. Launches Generic Fertility Treatment Injectable Cetrorelix® in the United States
-
Apr 2, 2024 Apotex to Acquire Searchlight Pharma, a Canadian Specialty Branded Pharmaceutical Leader
-
Feb 16, 2024 Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
-
Nov 21, 2023 Apotex Corp. Launches Teriparatide Injectable for Osteoporosis Treatment in the United States
-
Sep 5, 2023 Apotex Corp. Launches Brimonidine Tartrate Ophthalmic Solution, 0.1% in the United States
-
Aug 26, 2023 Apotex Corp. Launches Bendamustine Hydrochloride Injection in the United States
-
Apr 19, 2023 Apotex Receives FDA’s Drug Shortage Assistance Award
-
Apr 3, 2023 SK Capital completes acquisition of Apotex, a global leader in affordable pharmaceuticals
-
Sep 28, 2022 SK Capital to Acquire Apotex, a Global Leader in Affordable Pharmaceuticals
-
Jul 20, 2022 First Generic Alternative to Eliquis® Now Available in Canada
-
May 17, 2022 Apotex Launches Affordable Generic Option to Treat Relapsing Remitting Multiple Sclerosis
-
Apr 12, 2022 Apotex Corp. Launches Generic of Abraxane® in the United States
-
Feb 2, 2021 Apotex Corp. Issues Voluntary Nationwide Recall of Enoxaparin Sodium Injection, USP Due to Mislabeling of Syringe Barrel Measurement Markings
-
May 26, 2020 APOTEX CORP. DONATES CRITICAL MEDICINES IN THE FIGHT AGAINST COVID-19
-
May 26, 2020 Canada’s largest pharmaceutical manufacturer donates thousands of bottles of hand sanitizer to hospitals across Quebec
-
May 25, 2020 Toronto Company Launches Hiring Blitz During COVID-19
-
Apr 21, 2020 Canada’s Apotex Donates Two Million Dosages of Hydroxychloroquine to the Public Health Agency of Canada
-
Apr 17, 2020 Canada’s Apotex Donates Critical N95 Masks to Support Frontline Healthcare Workers
-
Apr 13, 2020 Canada’s Largest Pharmaceutical Company Produces Hand Sanitizer to Support the Fight Against COVID-19
-
Mar 23, 2020 APOTEX DONATES HYDROXYCHLOROQUINE FOR A CLINICAL STUDY TO PREVENT INFECTION FROM COVID-19 WITH FRONT LINE HEALTH CARE WORKERS
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Oct 8, 2025
Apotex supports launch of home-based cancer care with $1.5M donation
Apotex is helping bring oncology care directly into patients' homes through a $1.5 million donation to Sunnybrook Foundation. The contribution supports the launch of Cancer Care at Home, a new initiative under the Odette Cancer Program that delivers timely cancer care where patients live.
-
Oct 7, 2025
Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment
Searchlight Pharma Inc.(“Searchlight”), Apotex Inc’s (“Apotex”) Branded Medicines Division today announced it has entered into a strategic licensing agreement securing exclusive Canadian rights to linzagolix, a once-daily oral treatment developed by Kissei Pharmaceutical Co., Ltd. Linzagolix belongs to a class of medicines called GnRH antagonists.
-
Jul 2, 2025
Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats
Apotex Inc., the Canadian-based global health company, today announced that Health Canada has approved Aflivu™ (aflibercept), a biosimilar to Eylea®, indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema secondary to central or branch retinal vein occlusion, treatment of diabetic macular edema, and treatment of myopic choroidal neovascularization.